Can Pharma Ignore Turing’s Price Hikes?

Posted by Ed Schoonveld on Tue, Sep 22, 2015

Turing Pharmaceuticals caused uproar in political and medical communities with its price increase from $13.50 to $750 per pill in August for Daraprim, a toxoplasmosis treatment that was developed in 1953. It has added fuel to the already hot debate over prescription drug pricing. Turing’s CEO Martin Shkreli called the move a “smart business decision”, hardly a formulation that eases criticism in an environment where healthcare funding decisions are increasingly emotional and tough. “Price gouging” and “unscrupulous” are some of the terms used in reactions that have been dominating the news over the last few days.

Read More